The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
24-Nov-20
$1.5 billion
Target:
Cirque du Soleil
Acquiror:
Ad Hoc Group of Lenders
Advised the Company on its CCAA and Ch.15 proceedings and $1.5bn sale through a Sale and Investment Solicitation Process (SISP)
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
21-Dec-12
$3.7 billion
Target:
NewPage Corp.
Advised Stora Enso Oyj, a global paper, packaging and wood products producer headquartered in Helsinki, Finland, in connection with the Chapter 11 proceeding of NewPage, the largest North American coated-paper manufacturer
23-Nov-12
$NA
Target:
SAS Group
Acquiror:
Norwegian Government
Advised the Norwegian Government in relation to some specific issues in connection with the restructuring of SAS, the leading airline group in Northern Europe
21-Jul-09
$2.8 billion
Target:
Quebecor World Inc
Acted as financial advisor to Quebecor World on its CCAA / Chapter 11 restructuring
15-Oct-02
$3.2 billion
Target:
AT&T Canada
Advised AT&T Canada on a stand-alone financial restructuring
16-Jul-01
$982 million
Target:
Sterling Chemicals
Advised Sterling Chemicals in connection with its Chapter 11 proceedings